Clinical evaluation of MGC-NIPS method for noninvasive prenatal screening

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190708001

Enrollment

1320

Registered

2019-07-08

Start date

2019-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high risk pregnancy non invasive prenatal screening sensitivity specificity high risk pregnancy trisomy

Interventions

Down syndrome screening

Experimental Device

MGC&#45

NIPS

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: high risk pregnant woman who undergoing amniocentesis

Exclusion criteria

Exclusion criteria: multiple pregnancy cancer receiving blood product

Design outcomes

Primary

Measure	Time frame
accuracy of MGC-NIPS end of gold standard test sensitivity, specificity comparing to karyotyping	—

Secondary

Measure	Time frame
Immunologic response 24 weeks CD4 change,eGFR 24 weeks eGFR change,Proximal tubular function 24 weeks FEPO4, TmP/GFR, FEUA, UPCR, ,Lipid profiles 24 weeks Total cholesterl, Triglycerides, HDL, LDL	—

Countries

Thailand

Contacts

Public ContactVerayuth Praphanphoj

Medical Genome Company

vpthailand@yahoo.com+66 2 792 0726

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Clinical evaluation of MGC&#45;NIPS method for noninvasive prenatal screening